The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Novavax said Monday that the Food and Drug Administration was asking the company to run a new clinical trial of its vaccine.

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Novavax said on Wednesday the U.S. Food and Drug Administration had asked the company to produce more data on its COVID-19 ...

Under emergency use, vaccines can be removed even after a health emergency is considered to be over. Full approval from the FDA means a product can stay on the market even after a health emergency ...

As FDA Delays Novavax' COVID Vaccine Approval ... A decision on full approval – which rival mRNA shots from Moderna and Pfizer and its partner BioNTech already have - was due from the Food ...

The Novavax vaccine is the only COVID-19 booster in the United States ... A decision on full approval – which rival mRNA shots from Moderna and Pfizer and its partner BioNTech already have ...

As regards its COVID products, Pfizer records direct sales and alliance revenues from its partner, BioNTech BNTX for the COVID-19 vaccine, Comirnaty. Revenues from Pfizer’s COVID vaccine ...

Novavax makes the nation’s only traditional protein-based COVID-19 vaccine. It is still being sold under emergency use authorization — unlike mRNA vaccines made by Pfizer and Moderna that have ...